Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711671 · ClinicalTrials.gov registry record · Phase 1
A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Leap Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT01711671: Completed Phase 1 study, sponsored by Leap Therapeutics.
NCT01711671 is a Phase 1 study that has completed, run by Leap Therapeutics. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01711671, a Phase 1 study, has completed, sponsored by Leap Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
A study to evaluate the safety, efficacy and bone changes with combination therapy of intravenous (IV) infused DKN-01 and lenalidomide/dexamethasone, versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma (MM) patients
Primary Outcome
SUV as measured by NaF-PET/CT in both myeloma bone lesions and normal bone
Interventions
- DRUG Standard of Care
- DRUG DKN-01 300 mg
- DRUG DKN-01 600 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
What the finished NCT01711671 record still lists
NCT01711671 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 3 interventions - of which Standard of Care is the first listed.
NCT01711671 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01711671 about?
NCT01711671 is a clinical study titled "A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma". A study to evaluate the safety, efficacy and bone changes with combination therapy of intravenous (IV) infused DKN-01 and lenalidomide/dexamethasone, versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma (MM) patients
What is the current status of trial NCT01711671?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2013-05. Estimated completion is 2015-07.
What interventions are being tested in trial NCT01711671?
The interventions under investigation include: Standard of Care (DRUG), DKN-01 300 mg (DRUG), DKN-01 600 mg (DRUG).
Who is sponsoring clinical trial NCT01711671?
This trial is sponsored by Leap Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01711671's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia